Oruka Reports Positive Week 28 Results For ORKA-001 In Plaque Psoriasis; Stock Down

Oruka Therapeutics reported positive Week 28 results from the ongoing Phase 2a EVERLAST-A trial of ORKA-001 in patients with moderate-to-severe plaque psoriasis. The favorable mid-stage clinical update supports further development of the psoriasis treatment candidate and is likely to be a positive catalyst for ORKA shares.